The S&P/ASX 200 (INDEXASX: ^AXJO) (ASX: XJO) rose slightly higher today, up 0.8% to 5,042 points despite a wobbly banking sector keeping investors nervous.

These four shares all rose significantly further however, and here’s why:

Ziptel Ltd (ASX: ZIP) soared 14% to $0.365 after the company announced that its brand ambassador campaign had resulted in a significant uplift in installs. Ziptel now has 10 million installations, with the most recent 2 million coming in the past four weeks. This level of installs comes some nine months ahead of company forecasts and means that Ziptel can now focus on monetising its services.

With just $2.7 million in cash as at 31 December 2015 and heavy cash outflows, Ziptel will likely have to source additional capital to continue with its expansion plans. However, the whole company is valued at just $21m and, down 39% for the year, it is an interesting prospect today.

Pro Medicus Limited (ASX: PME) jumped 10% to $3.76 on news that the company had landed a A$21m+, 7-year deal with Mercy Health in the US, who will license the company’s Vision 7 technology for diagnosis of medical images. The deal could be the first of several with Mercy, which is the major shareholder in a healthcare supply chain business. It’s no surprise shareholders are excited, with today’s 10% rise carrying Pro Medicus’ shares up 145% for the year.

Freelancer Ltd (ASX: FLN) rose 5% to $1.27 on no news, after a period of heavy selling following the company’s most recent quarterly report. Possibly a slowdown in sales was to blame, with the $11m in revenue earned representing 30% of the revenue made in the past three quarters. If growth was accelerating, investors might expect this figure to be greater than 30%. However, Freelancer continues to deliver positive operating cash flow, and with $32m in the bank is extremely well funded to continue investing in itself and making acquisitions.

Freelancer shares are up 32% in the past 12 months.

Medical Developments International Ltd (ASX:MVP) leapt 10% to $5.81 on no news as investor expectations mount regarding the company’s ongoing expansion and recent entry into the ALL ORDINARIES (ASX: ^AXAO) (ASX: XAO) index. The company’s latest report wasn’t particularly remarkable, but with approval in 11 markets for its Penthrox product and a number of additional approvals pending, Medical Development’s growth is all ahead of it. Given the size of Medical Development’s target markets and the potential to take market share from narcotic painkillers, available growth certainly appears to be significant. However, much growth appears already priced in to the company.

Medical Developments shares are up 153% for the year.

Looking for an even better bet?

The technology that's going to REPLACE the Internet is already here...

Dollar for dollar, insiders are calling it one of the biggest new markets in the history of modern business...
NOW is the time to get in on the hush-hush industry that could be poised for growth of over 4,463%+ by 2020... And the 1 ASX stock that stands to grow YOUR money right alongside it! Simply click here to learn its name.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.